Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on BriaCell Therapeutics (BCT – Research Report), boosting the price target to $32.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Emily Bodnar’s rating is based on promising initial results from BriaCell Therapeutics’ Bria-OTS Phase 1 study. The first patient treated showed a complete resolution of a lung metastasis after only two months on the lowest dose, indicating the potential effectiveness of the therapy even at low doses. This study highlights the personalized nature of Bria-OTS, which could match a vast majority of breast cancer patients, enhancing its appeal.
Moreover, the company plans to expand the Bria-OTS trial to other cancers, such as prostate, lung, and melanoma, utilizing its adaptable technology platform. Additionally, after a reverse stock split and updated financial model, the price target was adjusted to $32, reflecting confidence in the company’s strategic direction and future potential. These factors collectively underpin the Buy rating for BriaCell Therapeutics.